Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group

Table 4 Published studies of adjuvant chemotherapy in early stage ovarian cancer

Study	Type of study	Treatment	Pts	5y RFS	5y OS
Young, 1990⁶	Prospective, randomized	Melphalan ³²P	68 73	80% 80%	81% 78%
Vergote, 1992¹	Prospective, randomized	Cisplatin ³²P	171 169	81% 83%	75% 81%
Bolis, 1995⁵	Prospective, randomized	Cisplatin ³²P	82 79	85% 65%	81% 79%
Young, 1999²⁰	Prospective, randomized	Cyclo/Cisplatin ³²P	107 98	77% 66%	84% 76%
Trope, 2000⁷	Prospective, randomized	Carboplatin No treatment	81 81	70% 71%	86% 85%
Trimbos, 2003⁸	Prospective, randomized	Platinum-based No treatment	224 224	76%* 68%	85% 78%
ICON1, 2003⁹	Prospective, randomized	Platinum-based No treatment	241 236	73%^@ 62%	79%^# 70%
Present study	Retrospective, nonrandomized	Paclitaxel/Carboplatin	69	79%	87%

RFS: relapse-free survival; OS: overall survival; *: p = 0.02; @: p = 0.01; #: p = 0.03

ISSN: 1471-2407